Efferocytosis in atherosclerosis

Nature Reviews Cardiology, Published online: 15 May 2024; doi:10.1038/s41569-024-01037-7In this Review, Adkar and Leeper describe the mechanisms of programmed cell death and efferocytosis, discuss how efferocytosis becomes impaired in atherosclerosis and other cardiometabolic diseases, and suggest potential strategies to target these pathways for the treatment of atherosclerotic cardiovascular disease.

Posted on: 14 May 2024 | 7:00 pm

Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?

Nature Reviews Cardiology, Published online: 07 May 2024; doi:10.1038/s41569-024-01014-0In 1993, Lincoff and Topol claimed that the thrombolytic treatment of ST-segment elevation myocardial infarction was suboptimal in many patients and gave an ‘illusion of reperfusion’. In this Perspective article, the authors propose that a similar illusion of revascularization exists for contemporary percutaneous revascularization in patients with coronary artery disease and ischaemia, and identify how outcomes might be improved.

Posted on: 6 May 2024 | 7:00 pm

No benefit of apoA-I infusion after myocardial infarction

Nature Reviews Cardiology, Published online: 03 May 2024; doi:10.1038/s41569-024-01031-zIn the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.

Posted on: 2 May 2024 | 7:00 pm

Stress and cardiovascular disease: an update

Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01024-yPhysiological responses to stress are thought to increase the risk of cardiovascular disease via haemodynamic, vascular and immune perturbations. In this Review, Vaccarino and Bremner focus on issues with the measurement of psychological stress and the underlying pathobiology connecting stress to the risk of cardiovascular disease.

Posted on: 1 May 2024 | 7:00 pm

Reply to ‘Screening for <i>Helicobacter pylori</i> infection in patients with cardiovascular and gastrointestinal disease’

Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01029-7Reply to ‘Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease’

Posted on: 1 May 2024 | 7:00 pm

Screening for <i>Helicobacter pylori</i> infection in patients with cardiovascular and gastrointestinal disease

Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01028-8Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease

Posted on: 1 May 2024 | 7:00 pm

The coronary sinus reducer improves angina symptoms in patients with stable CAD

Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01033-xFindings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.

Posted on: 24 April 2024 | 7:00 pm

Periodontal treatment reduces AF recurrence

Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01036-8Treatment for periodontal disease might reduce the recurrence of atrial fibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.

Posted on: 24 April 2024 | 7:00 pm